Oct-13 -

Leukemia Group / Elderly

EORTC 06012 – Gemtuzumab Ozogamycin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61 – 75 years old with previously untreated AML : a randomized phase III trial (AML-17) of the EORTC – LG and the GIMEMA-ALWP.

EORTC found that the addition of gentuzumab ozogamicin (GO) prior to standard induction treatment provides no benefit for patients of 61 to 75 years old with acute myelogenous leukemia (AML).


Go to Top